WALTHAM, MA • 2020-05-19

BostonGene Announces Acceptance of Seven Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020

5 min to read

Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States
Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States

WALTHAM, MA, May 19, 2020 — BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting.  All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

“We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGene‘s advanced precision medicine capabilities and our commitment to transform the lives of cancer patients,” said Andrew Feinberg, President & CEO at BostonGene.

Details of abstract presentations are as follows:

Abstract Number: 8055*
Title: “Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Krystle Nomie, PhD, BostonGene
Poster: 388

Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib.

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: 6561*
Title: “Immune functional portraits of head and neck cancer using next generation sequencing”
Session: Head and Neck Cancer
Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital
Poster: 222

BostonGene’s comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment.

Research conducted with Massachusetts General Hospital

Abstract Number: 8054*
Title: “Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients”
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Cody Ramirez at Washington University in St Louis
Poster: 387

Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy.

Research conducted with Washington University in St Louis

Abstract Number: e20065
Title: “Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma”
First Author: Krystle Nomie, PhD, BostonGene

Research conducted with The University of Texas MD Anderson Cancer Center

Abstract Number: e21026
Title: “Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies”
First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Research conducted with Massachusetts General Hospital

Abstract Number: e17106
Title: “Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma”
First Author: James Hsieh, MD, PhD at Washington University in St. Louis

Research conducted with Washington University in St Louis

Abstract Number:  e17506
Title: “Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome”
First Author: Eric H. Kim, MD at Washington University in St. Louis

Research conducted with Washington University in St Louis

*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com